chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: U
Vaccine: FLUC4
Symptoms: Injection site mass, Injection site rash
Clinical narrative: A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from  was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases 202004678, 202004696, 202004697, 202004698, 202004700, 202004701, 202004702, 202004703, 202004704, 202004705 and 202004706  due to the same reporter.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional document received on 12-Jan-2021 from other health professional via The Agency (reference number: SEQW21-00149): Two additional reporters added. No changes in narrative.  Company comment: The patient developed vaccination site mass and vaccination site rash on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. No information regarding concomitant medications and medical history was provided. Considering all information above, causal relationship for both events is assessed as possibly related. (defaults to ''related''in the safety database for reporting purposes).; Sender's Comments: The patient developed vaccination site mass and vaccination site rash on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. No information regarding concomitant medications and medical history was provided. Considering all information above, causal relationship for both events is assessed as possibly related. (defaults to ''related''in the safety database for reporting purposes).
Sex: U
Vaccine: FLUC4
Symptoms: Injection site mass, Injection site rash, Injection site swelling
Clinical narrative: A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from  was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases  202004678, 202004696, 202004697, 202004698, 202004699, 202004701, 202004702, 202004703, 202004704, 202004705 and 202004706  due to the same reporter.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional information received on 12-Jan-2021 from other health professional (reference number: SEQW21-00149) (being processed together): Two reporters were added. Reference numbers added. No changes in narrative.  Company comment: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.; Sender's Comments: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.
Sex: U
Vaccine: FLUC4
Symptoms: Injection site mass, Injection site rash
Clinical narrative: A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases  202004678, 202004696, 202004697, 202004698, 202004699, 202004700, 202004702, 202004703, 202004704, 202004705 and 202004706  due to the same reporter.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional information received on 12-Jan-2021 from other health professional (reference number: SEQW21-00149) (being processed together): Two reporters were added. Reference numbers added. No changes in narrative.  Company comment: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.; Sender's Comments: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.
Sex: U
Vaccine: FLUC4
Symptoms: Vaccination site mass, Vaccination site rash
Clinical narrative: A bump at the site of administration of the vaccine; A 3 inch rash at the site of administration of the vaccine; This spontaneous case from was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849, expiry date: 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment.   The case was assessed as non-serious.  This case is linked with cases: 202004697, 202004698, 202004699, 202004706, 202004701, 202004703, 202004704, 202004705, 202004678, 202004696 and 202004700.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) and processed together with additional information received on 12-Jan-2021 from other health professional (reference number: SEQW21-00149): Two reporters were added. Reference numbers added. No changes in narrative.  Company comment: The patient developed vaccination site mass and vaccination site rash on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. No information regarding concomitant medications and medical history was provided. Considering all information above, causal relationship for both events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).; Sender's Comments: The patient developed vaccination site mass and vaccination site rash on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. No information regarding concomitant medications and medical history was provided. Considering all information above, causal relationship for both events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).
Sex: U
Vaccine: FLUC4
Symptoms: Injection site mass, Injection site rash
Clinical narrative: A bump at the site of administration of the vaccine; A 3 inch rash at the site of administration of the vaccine; This spontaneous case from  was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849, expiry date: 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment.   The case was assessed as non-serious.  This case is linked with cases: 202004697, 202004698, 202004699, 202004706, 202004701, 202004702, 202004704, 202004705, 202004678, 202004696 and 202004700 (same reporter).  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional information received on 12-Jan-2021 from other health professional via The Agency (reference number: SEQW21-00149) (being processed together): Two additional reporters added. Additional reference numbers added. No changes in narrative.  Company comment: The patient developed vaccination site mass and vaccination site rash on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. No information regarding concomitant medications and medical history was provided. Considering all information above, causal relationship for both events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).; Sender's Comments: The patient developed vaccination site mass and vaccination site rash on the same day after vaccination with the suspect product, Flucelvax QIV. Chronology is suggestive. No information regarding concomitant medications and medical history was provided. Considering all information above, causal relationship for both events is assessed as possibly related. (defaults to ''related'' in the safety database for reporting purposes).
Sex: U
Vaccine: FLUC4
Symptoms: Vaccination site mass, Vaccination site rash
Clinical narrative: A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from  was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases 202004678, 202004696, 202004697, 202004698, 202004699, 202004700, 202004701, 202004702, 202004703, 202004705 and 202004706 (due to the same reporter).  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional information received on 12-Jan-2021 from other health professional (reference number: SEQW21-00149) (being processed together): Two reporters were added. Reference numbers added. No changes in narrative.  Company comment: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.; Sender's Comments: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.
Sex: U
Vaccine: FLUC4
Symptoms: Injection site extravasation, Injection site rash
Clinical narrative: A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases 202004678, 202004696, 202004697, 202004698, 202004699, 202004700, 202004701, 202004702, 202004703, 202004704 and 202004706 due to the same reporter.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional document received on 12-Jan-2020 from other health professional (reference number: SEQW21-00149) (being processed together): Two additional reporters added. Narrative was not amended.  Company comment: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.; Sender's Comments: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.
Sex: U
Vaccine: FLUC4
Symptoms: Administration site rash, Injection site mass
Clinical narrative: A bump and a 3 inch rash at the site of administration of the vaccine; A bump and a 3 inch rash at the site of administration of the vaccine; This spontaneous case from  was received on 24-Sep-2020 from other non-health professional via The Agency (reference number: SEQW20-02263) and concerned a patient of an unknown age and gender.  The patient's medical history and concomitant medications were not reported.   On 17-Sep-2020, the patient was vaccinated with Flucelvax QIV (influenza vaccine, subunit influenza virus vaccine polyvalent, dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid) for influenza prophylaxis. The batch number reported was 283849 and expiry date was 30-Jun-2021.   On the same day, after receiving Flucelvax QIV, the patient developed a bump and a 3-inch rash at the site of administration of the vaccine. The patient did not receive any treatment measures associated with the events.  On an unspecified date in Sep-2020, the patient recovered from the events.  The reporter did not provide a causality assessment to Flucelvax QIV.   The case was assessed as non-serious.  This case is linked to cases 202004678, 202004696, 202004697, 202004698, 202004699, 202004700, 202004701, 202004702, 202004703, 202004704 and 202004705  due to the same reporter.  Additional non-significant information received on 06-Jan-2021 from other non-health professional via The Agency (reference number: SEQW21-00065) with additional information received on 12-Jan-2021 from other health professional (reference number: SEQW21-00149) (being processed together): Two reporters were added. Reference numbers added. No changes in narrative.  Company comment: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.; Sender's Comments: A patient of an unknown age and gender was administered Flucelvax QIV vaccine. On the same day, after receiving Flucelvax QIV, the patient developed vaccination site rash and vaccination site mass. The patient's medical history and concomitant medications were not reported. Chronology is plausible. Causality is assessed as possibly related for both events.
Age: 28.0
Sex: F
Vaccine: FLUC4
Symptoms: Erythema, Tenderness
Clinical narrative: A localized reaction with erythema and tenderness in the arm; A localized reaction with erythema and tenderness in the arm; This spontaneous case from the  was received on 11-Dec-2020 via The Agency (reference number: SEQW20-05712), reported by a physician and concerned a 28-year-old, female patient.  The patient's relevant medical history and concomitant medications were not reported.  On 04-Sep-2020, the patient was vaccinated with Flucelvax Quadrivalent (influenza vaccine, subunit influenza virus vaccine polyvalent; dose: 0.5 ml, route of administration: intramuscular and anatomical location: not reported) for influenza prophylaxis. The batch number reported was 279847 and expiry date was 30-Jun-2021.  On an unreported date in 2020, after receiving Flucelvax Quadrivalent, the patient developed a localized reaction with erythema and tenderness in the arm. The patient did not receive any treatment.  On an unreported date in 2020, within 48h to 72h, the patient recovered from the events.  The reporter did not provide a causality assessment.  The reporter assessed the events as non-serious.  This case is linked to cases 202007627, 202007628 and 202007631 due to the same reporter.  Company comment: A 28-year-old patient was administered Flucelvax Quadrivalent. An unknown amount of time after receiving Flucelvax Quadrivalent, the patient developed a localized reaction with erythema and tenderness in the arm. Causality is assessed as possibly related for both events.; Sender's Comments: A 28-year-old patient was administered Flucelvax Quadrivalent. An unknown amount of time after receiving Flucelvax Quadrivalent, the patient developed a localized reaction with erythema and tenderness in the arm. Causality is assessed as possibly related for both events.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling cold, Headache, Nausea, Pain in extremity, Skin warm
Clinical narrative: About 5-6 hours after the shot I started to experience nausea. It is night time so I attempted to sleep. I just woke up with the urge to vomit. Have been vomiting now for more or less 10minutes (all of what I ate during dinner).   Other symptoms include slight headache, feeling slightly warm although I have not checked my temperature and also at the same time slightly cold, and pain in the right arm.   On the previous dose the only symptom I had was pain in my left arm (I switched sides this time around although don?t think that is relevant)
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Sleep disorder, Vomiting
Clinical narrative: About 5-6 hours after the shot I started to experience nausea. It is night time so I attempted to sleep. I just woke up with the urge to vomit. Have been vomiting now for more or less 10minutes (all of what I ate during dinner).   Other symptoms include slight headache, feeling slightly warm although I have not checked my temperature and also at the same time slightly cold, and pain in the right arm.   On the previous dose the only symptom I had was pain in my left arm (I switched sides this time around although don?t think that is relevant)
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Joint range of motion decreased, Lymphadenopathy, Pain, Tenderness
Clinical narrative: Moderate to severe swelling of the left subclavicular lymph node and armpit lymph node. Swelling impacted range of motion. The areas were tender to touch and motion. Swelling lasted 3 days.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Induration, Swelling
Clinical narrative: Large hard bump on day 1, day 2 it became smaller but more spread out and red. Hot and itchy from day 1. Taken benadryl both days. Slight improvement.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cough, Dyspnoea, Fatigue, Influenza virus test negative
Clinical narrative: 05/04/2021 4:30am - 05/05/2021 9:00 - aches, chills 05/04/2021 - 5/13/2021 - fatigue 05/04/2021 12:00pm - vomited  05/04/2021 7:00pm - fever 100.6°F - took fever reducer (ibuprofen) 05/05/2021 4:00am - 05/11/2021 9:00am - sore throat, coughing,  congestion, heavy breathing (hard to breathe)
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pain, Pyrexia, Respiratory tract congestion, SARS-CoV-2 test negative
Clinical narrative: 05/04/2021 4:30am - 05/05/2021 9:00 - aches, chills 05/04/2021 - 5/13/2021 - fatigue 05/04/2021 12:00pm - vomited  05/04/2021 7:00pm - fever 100.6°F - took fever reducer (ibuprofen) 05/05/2021 4:00am - 05/11/2021 9:00am - sore throat, coughing,  congestion, heavy breathing (hard to breathe)
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Streptococcus test negative, Vomiting
Clinical narrative: 05/04/2021 4:30am - 05/05/2021 9:00 - aches, chills 05/04/2021 - 5/13/2021 - fatigue 05/04/2021 12:00pm - vomited  05/04/2021 7:00pm - fever 100.6°F - took fever reducer (ibuprofen) 05/05/2021 4:00am - 05/11/2021 9:00am - sore throat, coughing,  congestion, heavy breathing (hard to breathe)
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Gingival bleeding, Headache, Myalgia, Pyrexia, Stomatitis
Clinical narrative: Headache, muscle ache, fever, gum bleeding, oral sore
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature increased, Cough, Diarrhoea, Dizziness, Fatigue
Clinical narrative: Severe headache ongoing all day; body and muscle aches all day; extreme fatigue all day; dry cough over 4 hours; temperature of 100.3 for several hours, dizziness all day; diarrhea twice in the evening; sore throat all day
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Myalgia, Oropharyngeal pain, Pain
Clinical narrative: Severe headache ongoing all day; body and muscle aches all day; extreme fatigue all day; dry cough over 4 hours; temperature of 100.3 for several hours, dizziness all day; diarrhea twice in the evening; sore throat all day
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chest pain, Chills, Dyspnoea, Fatigue
Clinical narrative: 4/28  4am Fatigue 8am  joint pain 10 am chest pain, difficulty breathing  8pm chills, sweating 4/29 Chest pain   4/30 2am vomite, chest pain, sweating, difficulty breathing. 3am myocarditis.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Hyperhidrosis, Myocarditis, Vomiting
Clinical narrative: 4/28  4am Fatigue 8am  joint pain 10 am chest pain, difficulty breathing  8pm chills, sweating 4/29 Chest pain   4/30 2am vomite, chest pain, sweating, difficulty breathing. 3am myocarditis.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Magnetic resonance imaging abnormal, Transverse sinus thrombosis
Clinical narrative: Patient found to have asymptomatic intracranial sinus vein thrombosis in the transverse/sigmoid sinus on the left side
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Headache, Pain in extremity
Clinical narrative: Extreme headaches persisting for over a week, piercing and throbbing headaches at temples throughout the day, called my doctor but only heard back from doctor through exchange, who said to take Tylenol and it?s probably nothing. I did not take Tylenol as I wanted to see if and  when it would be better. Eventually lessened after persistent headaches for over a week. Slowly got to be less and less, but am still having headaches off and on, whereas I am not the headachy type of person.  lightheadedness, feeling dizzy and light in head, strong for about a week then slowed down but also still getting it from time to time. No treatment done.  very sore arm. Was expected, but figured I should mention it while mentioning the other things
Age: 23.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Myalgia, Pyrexia
Clinical narrative: Headache, fatigue, muscle pain (not localized), fever (~100F)
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Diarrhoea, Dizziness, Headache, Injection site pain
Clinical narrative: Headache, feeling sick, weakness, swelling at injection site, pain at injection site, diarrhea, dizziness.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site swelling, Malaise
Clinical narrative: Headache, feeling sick, weakness, swelling at injection site, pain at injection site, diarrhea, dizziness.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Erythema, Feeling hot, Flushing, Pruritus
Clinical narrative: AT 25 MINUTE POST VACCINATION, PATIENT APPROACHED ME AND ASKED IF WAS ABLE TO LEAVE. WHEN ASKING HER HOW SHE FELT, SHE STATED "HOT, FLUSHED, REDNESS TO FACE, AND A LITTLE BIT OF CHEST TIGHTNESS" PATIENT DID TAKE BENADRYL 50MG PRIOR TO 2ND DOSE OF VACCINATION.  STATES SHE WAS ALSO ITCHY AT UPPER EXTREMITIES.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pyrexia
Clinical narrative: Fever, head ache continuously from 2nd day of vaccination. didn't  took any medication for 9 days. on 13th may, took 1 tablet Tylenol
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Urticaria
Clinical narrative: Multiple hives noted over posterior aspects of bilateral thighs and knees, bilateral  elbows and bilateral axillary areas.  Vaseline and lotion gave temporary relief.  Hives returned back the following day.  This time Rashes completely stopped after taking Zyrtec.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Headache, Hypoaesthesia, Injection site erythema, Injection site induration
Clinical narrative: Numbness started on the left side of my scalp and turned into tingling/itching as well. This continued to spread across my entire scalp, face and back of my neck I am still dealing with it. Injection site is also red, hard and swollen, fever, extreme headache, sharp pain through shoulder and spine
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site swelling, Paraesthesia, Pruritus, Pyrexia, Spinal pain
Clinical narrative: Numbness started on the left side of my scalp and turned into tingling/itching as well. This continued to spread across my entire scalp, face and back of my neck I am still dealing with it. Injection site is also red, hard and swollen, fever, extreme headache, sharp pain through shoulder and spine
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Blood creatinine increased, Haemoglobin decreased, Nausea, Platelet count decreased, Thrombocytopenia
Clinical narrative: Nausea, vomiting, thrombocytopenia (?ITP)
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Nausea, vomiting, thrombocytopenia (?ITP)
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Acoustic stimulation tests, Tinnitus
Clinical narrative: Developed Tinnitus (constant high pitch ringing) in both ears about a week after first dose.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site pruritus, Injection site rash, Injection site swelling, Rash erythematous
Clinical narrative: SYMPTOMS  swollen and noticeably raised bump over injection site itchy red rash radiating around injection site (wasn't raised or bumpy though)  TIME AND COURSE swelling appeared within 12 hours; lasted about 3 days rash appeared within 36 hours; lasted about 5 days  TREATMENT ibuprofen 2x day for 4 days, starting day after injection  anti-itch cream 1x day for 2 days starting day 5 after injection (didn't help rash)
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Pain, Pyrexia
Clinical narrative: Received Pfizer- got chills, body ache, had 102 fever, joints hurt.
Age: 20.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Asthenia, Dizziness, Headache
Clinical narrative: I experienced a great head ache followed by weakness and then I experienced a great stomach ache and dizziness.
Age: 22.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dyspnoea, Full blood count, Headache, Metabolic function test, Nausea
Clinical narrative: Fever, Headache, Shortness of Breath, Nausea, Body aches, difficulty tolerating drinking
Age: 22.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Pain, Pyrexia, Water pollution
Clinical narrative: Fever, Headache, Shortness of Breath, Nausea, Body aches, difficulty tolerating drinking
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Cough, Diarrhoea, Fatigue, Headache
Clinical narrative: Fever or Chills  Cough  Fatigue  Muscle or body aches  Headache  Congestion or running nose  Diarrhea
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pain, Pyrexia, Respiratory tract congestion, Rhinorrhoea
Clinical narrative: Fever or Chills  Cough  Fatigue  Muscle or body aches  Headache  Congestion or running nose  Diarrhea
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Fever or Chills  Cough  Fatigue  Muscle or body aches  Headache  Congestion or running nose  Diarrhea
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Crying, Incorrect route of product administration, Injection site pain, Joint range of motion decreased
Clinical narrative: Excruciating pain in right arm, enough to cause crying - unable to lift arm. Vaccine given too high up in arm.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Adenovirus test, Bordetella test negative, COVID-19, Enterovirus test negative, Human rhinovirus test
Clinical narrative: Patient has previous covid test positive from 4/18/21  04/19/21 1301  Respiratory virus detection panel  Collected: 04/19/21 0943 | Final result | Specimen: Swab from Nasopharynx   Adenovirus Not Detected Mycoplasma pneumoniae Not Detected Chlamydophila pneumoniae Not Detected Parainfluenza Not Detected COVID-19 SARS-CoV-2 Overall Result DetectedCritical  Enterovirus/Rhinovirus Not Detected Coronavirus Not Detected Respiratory Synctial Virus Not Detected Influenza A Not Detected Bordetella pertussis Not Detected Influenza B Not Detected Bordetella parapertussis Not Detected
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Influenza A virus test negative, Influenza B virus test, Mycoplasma test, Respiratory syncytial virus test negative, SARS-CoV-2 test positive
Clinical narrative: Patient has previous covid test positive from 4/18/21  04/19/21 1301  Respiratory virus detection panel  Collected: 04/19/21 0943 | Final result | Specimen: Swab from Nasopharynx   Adenovirus Not Detected Mycoplasma pneumoniae Not Detected Chlamydophila pneumoniae Not Detected Parainfluenza Not Detected COVID-19 SARS-CoV-2 Overall Result DetectedCritical  Enterovirus/Rhinovirus Not Detected Coronavirus Not Detected Respiratory Synctial Virus Not Detected Influenza A Not Detected Bordetella pertussis Not Detected Influenza B Not Detected Bordetella parapertussis Not Detected
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Heart rate increased
Clinical narrative: I experienced a very high resting heart rate about 9-10 hours after receiving the Johnson & Johnson vaccine. My resting heart rate was around 100 BPM and when I?d walk a short distance across a room itd go up to around 150 BPM. It resolved approximately around 4 am on 5/7/2021
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Pain
Clinical narrative: Chills and body aches started @ Midnight after receiving the vaccine and lasted for 24 hours
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Decreased appetite, Diarrhoea, Dyspnoea
Clinical narrative: weakness diarrhea poor appetite fever chills shortness of breath
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test
Clinical narrative: weakness diarrhea poor appetite fever chills shortness of breath
Age: 0.17
Sex: M
Vaccine: DTAP, HIBV, PNC13, RV1
Symptoms: Crying, Pain in extremity, Swelling, Tenderness
Clinical narrative: R thigh swelling, pain, tenderness, crying
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Dizziness, Headache, SARS-CoV-2 test
Clinical narrative: cough, headaches, dizzy  Tessalon Perles
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Blood culture, COVID-19, COVID-19 pneumonia, Chest X-ray, Condition aggravated
Clinical narrative: body aches to "back, legs, knees and ankles," loss of appetite, fatigue and mild cough. Hypoxia  Pneumonia due to COVID-19 virus  Nausea & vomiting  COVID-19 virus infection
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Decreased appetite, Fatigue, Hypoxia, Nausea
Clinical narrative: body aches to "back, legs, knees and ankles," loss of appetite, fatigue and mild cough. Hypoxia  Pneumonia due to COVID-19 virus  Nausea & vomiting  COVID-19 virus infection
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Vomiting
Clinical narrative: body aches to "back, legs, knees and ankles," loss of appetite, fatigue and mild cough. Hypoxia  Pneumonia due to COVID-19 virus  Nausea & vomiting  COVID-19 virus infection
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site pruritus, Injection site warmth
Clinical narrative: Large approximately 2? in diameter at this time , red, hard itchy spot at injection sight. Warm to the touch  Appeared a few hours after receiving  injection.
Age: 93.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19 pneumonia, Dyspnoea, Pyrexia
Clinical narrative: Short of breath Fever COVID-19 pneumonia  prednisone 40 mg oral Daily
Age: 15.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Client felt light-headed and dizziness.  BP 90/40 and 102/63, HR 63.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: 114/72, 99 Pulse ox, heart 68. Pts. mono alerted nurses to fire rescue that boy was dizzy/lightheaded.  His fitals were checked and drank water.  He instantly began to feel better and refused further treatment.
Age: 50.0
Sex: M
Vaccine: COVID19
Symptoms: Burning sensation, Headache
Clinical narrative: Burning sensation type-headache.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Chills, Cough, Dry eye, Dry mouth
Clinical narrative: Fever 102.7 for three days, chills, lethargy for a week, bad muscle aches, dry mouth and eyes, very bad headache, stuffy nose, cough, nausea, skin very sensitive like a sunburn, sharp pains at spine, , chest tightness, some symptoms continue today... a month later. I was way sicker from the vaccine than from actually having COVID.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lethargy, Myalgia, Nasal congestion, Nausea
Clinical narrative: Fever 102.7 for three days, chills, lethargy for a week, bad muscle aches, dry mouth and eyes, very bad headache, stuffy nose, cough, nausea, skin very sensitive like a sunburn, sharp pains at spine, , chest tightness, some symptoms continue today... a month later. I was way sicker from the vaccine than from actually having COVID.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Sensitive skin, Spinal pain
Clinical narrative: Fever 102.7 for three days, chills, lethargy for a week, bad muscle aches, dry mouth and eyes, very bad headache, stuffy nose, cough, nausea, skin very sensitive like a sunburn, sharp pains at spine, , chest tightness, some symptoms continue today... a month later. I was way sicker from the vaccine than from actually having COVID.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Sinus tachycardia
Clinical narrative: Post vaccine pt complained of chest pain. Denied other symptoms. Pt noted symptoms worsened with sitting/leaning and improved while standing. EMS evaluation revealed sinus tachycardia, HR 140, BP 164/94. Repeat vitals normal sinus rhythm. Symptoms resolved and pt went home.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site erythema, Injection site mass, Injection site pruritus, Injection site swelling, Injection site warmth
Clinical narrative: Right after leaving the facility I started itching on my left arm . When I got home I had a red raised lump on the injection site. It was very hot, it itched and it hurt
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus
Clinical narrative: Right after leaving the facility I started itching on my left arm . When I got home I had a red raised lump on the injection site. It was very hot, it itched and it hurt
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Full blood count normal, Injection site erythema, Injection site pain, Injection site pruritus
Clinical narrative: Experienced a round red area at injection site within 24 hours of injection.  Site was painful and itchy at times.  Now, 2 weeks later, redness has faded but is still present and site itches at times.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Metabolic function test, Mobility decreased, Peripheral swelling
Clinical narrative: Full blown RA every joint in my body severely painful with no relief. Swelling of hands and feet. Loss of strength in hands, wrists and arms. Inability to lift arms beyond shoulders and shoulders severely painful. Onset approximately 2 weeks following second dose and finally resulted in doctor visit and blood work. All RA numbers off the charts. Prescribed steroids for swelling and tramadol  for pain. First 24 hours approximately 70% improvement of symptoms. Currently starting second day. Also referral was done to a rheumatologist.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Rheumatoid arthritis, Rheumatoid factor increased
Clinical narrative: Full blown RA every joint in my body severely painful with no relief. Swelling of hands and feet. Loss of strength in hands, wrists and arms. Inability to lift arms beyond shoulders and shoulders severely painful. Onset approximately 2 weeks following second dose and finally resulted in doctor visit and blood work. All RA numbers off the charts. Prescribed steroids for swelling and tramadol  for pain. First 24 hours approximately 70% improvement of symptoms. Currently starting second day. Also referral was done to a rheumatologist.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Lip swelling
Clinical narrative: At midnight, 9 hours after dose, lips started swelling. Got progressively worse for 3 hours. Disappeared after 24 hours.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Loss of consciousness, Nausea, Pain in extremity, Vomiting
Clinical narrative: I woke at 4 am with intense chills and nausea.  I looked at my watch at 5:24 waiting for my husband's alarm to go off. I thought to myself that I felt I was going to throw up. Next thing I know, my husband is yelling and the dogs are barking around me. I'm drowning in my vomit (laying on my back because the arm hurt). He sits me up and I throw up multiple times all over the bed. I had blacked out while vomiting and without him there, I could have died.
Age: 64.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Acute kidney injury, Blood urine present
Clinical narrative: Acute kidney failure, unspecified Blood in urine
Age: 80.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain, Acute kidney injury, Vomiting
Clinical narrative: Acute kidney failure, unspecified ABDOMINAL PAIN VOMITING
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Dizziness, Fatigue, Headache
Clinical narrative: 102 degree fever, worst headache ever experienced, chills, nausea, inability to eat, fatigue. all occuring simultaneously from may 10 at 10pm to may 13 at 3pm   at 3pm on may 13 symptoms shifted to extreme dizziness, nausea, and inability to sit, stand or raise arms in lying position without feeling overwhelming sensation of being about to faint or black out. vision tunnels from standing longer than one minute. this is ongoing as of writing this may 14th.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, Tunnel vision
Clinical narrative: 102 degree fever, worst headache ever experienced, chills, nausea, inability to eat, fatigue. all occuring simultaneously from may 10 at 10pm to may 13 at 3pm   at 3pm on may 13 symptoms shifted to extreme dizziness, nausea, and inability to sit, stand or raise arms in lying position without feeling overwhelming sensation of being about to faint or black out. vision tunnels from standing longer than one minute. this is ongoing as of writing this may 14th.
Sex: U
Vaccine: MMR, UNK, UNK
Symptoms: Product preparation issue
Clinical narrative: MMR II was reconstituted with normal saline instead of the supplied Merck Diluent; This spontaneous report as received from a office manager referring to a patient of unknown age and gender.  The patient's medical history, concomitant medications, drug allergies, or reactions were not reported    On 16-APR-2021, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) (lot # S035356 has been verified to be a valid lot number for measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA), expiration date 05-NOV-2021) for prophylaxis(strength, dose, administration route and frequency were not provided) . It was reported that the vaccine was reconstituted with Normal saline 9%( sodium chlorine) instead of merck sterile diluent (product preparation error).
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Blood test, Chest discomfort, Computerised tomogram, Dizziness
Clinical narrative: HEAD PRESSURE; HEART PALPITATIONS; FEELING OF A RUSH TO THE HEAD AFTER EATING; DRY EYES; RINGING IN THE EARS; MYALGIA; GI ISSUES LIKE BUBBLING STOMACH; FATIGUE; STIFFNESS IN THE NECK/ MUSCLE TIGHTNESS IN THE JAW; DROOPING RIGHT EYE LID; CHEST PRESSURE; ANXIETY; DIZZINESS AFTER GOING FOR A WALK; HEADACHE; This spontaneous report received from a patient concerned a 37 year old male. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A, and batch number: 042A21A expiry: UNKNOWN) dose was not reported, administered on 07-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 2021, the subject experienced dizziness after going for a walk. On 2021, the subject experienced anxiety. On 2021, the subject experienced headache. On APR-2021, the subject experienced drooping right eye lid. On APR-2021, the subject experienced chest pressure. On APR-2021, the subject experienced stiffness in the neck/ muscle tightness in the jaw. Laboratory data included: Blood test (NR: not provided) NOT REPORTED. On 07-APR-2021, the subject experienced fatigue. On 08-APR-2021, the subject experienced gi issues like bubbling stomach. On 09-APR-2021, the subject experienced myalgia. On 18-APR-2021, Laboratory data included: Blood test (NR: not provided) did not find any specific signs causing his symptoms, and CT scan (NR: not provided) did not find any specific signs causing his symptoms. On 25-APR-2021, the subject experienced ringing in the ears. On 26-APR-2021, Laboratory data included: Blood test (NR: not provided) also found nothing unusual. On an unspecified date, the subject experienced head pressure, heart palpitations, feeling of a rush to the head after eating, and dry eyes. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from gi issues like bubbling stomach, feeling of a rush to the head after eating, and dizziness after going for a walk, had not recovered from fatigue, myalgia, head pressure, heart palpitations, chest pressure, anxiety, and ringing in the ears, and the outcome of dry eyes, stiffness in the neck/ muscle tightness in the jaw, drooping right eye lid and headache was not reported. This report was non-serious.; Sender's Comments: V0: Medical assessment comments not required as per standard procedure as the case is assessed non serious.